Botanix Pharmaceuticals Ltd has released a press release.
Update on BTX 1801 Phase 2a Clinical Study
Filed with ASX ·
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Botanix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Botanix Pharmaceuticals
- FDA Clears Development Path for BTX 1801
- Response to ASX Price Query
- New Antimicrobial Data and Conference Presentation
- Appendix 4E and Annual Report to Shareholders
- BTX 1801 Phase 2a Antimicrobial Study Underway
Later from Botanix Pharmaceuticals
- Antimicrobial Data Published in Peer-Reviewed Journal
- Phase 2a Study Shows BTX 1801 Eradicates S. Aureus
- Botanix receives A$6.87m R&D Tax Incentive Refund
- BTX 1702 Rosacea Study Approval
- Botanix Update on BTX 1801 Clinical Development
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals